Psychedelic Patents are Broken Because the Patent System Is Broken
James Bessen’s research cited in “Psychedelic Patents are Broken Because the Patent System Is Broken” article in VICE, May 09, 2022.
Category: All Articles
‘Occupational segregation’ drives down women’s pay, says fed labor exec
TPRI’s research cited in ‘Occupational segregation’ drives down women’s pay, says fed labor exec article in WRAL TechWire, March 14, 2022.
Has Strategic Management Overlooked the Role of Purpose? What Experts Say
Timothy Simcoe quoted in MIT Sloan Review Management, February 28, 2022.
Profit Taxation, R&D Spending, and Innovation
By Andreas Lichter, Max Löffler, Ingo E. Isphording, Thu-Van Nguyen, Felix Poege, Sebastian Siegloch
Advances in pharmaceuticals and vaccines, robotics and artificial intelligence dominate newspaper headlines.
Do Incentives Matter for Hospitals?
By Tal Gross, Adam Sacarny, Maggie Shi & David Silver
America spends about 6 cents of every dollar at its hospitals. A natural question to ask: why not just pay those hospitals less?
How important is price variation between health insurers?
By Stuart V. Craig, Keith Marzilli Ericson, and Amanda Starc
We examined how prices vary between insurers for the same procedure at the same hospital, using a dataset of all commercial Massachusetts hospital claims.
The role of TRIPS in encouraging pharmaceutical technological diffusion in developing countries
Iain Cockburn, Tim Wilsdon, Michele Pistollato, Rajini Jayasuriya, and Thomas Watson
The 1995 TRIPS Agreement between member states of the World Trade Organization (WTO) defines minimum standards of intellectual property (IP) protection and enforcement.
How big technology systems are slowing innovation
James Bessen’s article “How big technology systems are slowing innovation: The great IT revolution is no longer promoting economic dynamism. It’s preventing it” in the MIT Technology Review February 17, 2022
Tech ads at the Super Bowl offered a shiny — or is it dark? — vision of the future
James Bessen quoted in The Washington Post, February 14, 2022.
US Insurer Spending on Ivermectin Prescriptions for COVID-19
Insurers heavily subsidize the cost of ivermectin prescriptions for COVID, despite the lack of evidence that ivermectin is effective for COVID. In a new paper, published in JAMA, Questrom professor and TPRI co-lead Rena Conti with colleagues Kao-Ping Chua and Nora Becker (both University of Michigan) estimate that U.S. insurers may have wasted $2.5 million on these drugs in the week of August 13, 2021 alone.